Although approved by the Food & Drug Administration (FDA) for some patients with rheumatoid arthritis (108), Anakinra is only moderately effective and is inferior to TNF-α inhibitors, indicating its poor applicability (109). The gene discussed is TNF; the disease is rheumatoid arthritis.